Uniquity Bio Advances Esophageal Drug Toward Phase 3 Trial

Uniquity Bio

MALVERN, PA — Uniquity Bio plans to begin a pivotal Phase 3 trial of its experimental esophageal disease treatment in early 2027 after reporting statistically significant improvements in swallowing symptoms and tissue inflammation in a midstage clinical study, advancing a potential new therapy for a chronic condition affecting an estimated 470,000 Americans.

The Blackstone Life Sciences-backed biotechnology company reported that solrikitug met both primary endpoints in its Phase 2 ALAMERE trial involving adults with eosinophilic esophagitis, or EoE, an inflammatory disease that can cause difficulty swallowing and damage to the esophagus.

At 24 weeks, the treatment produced placebo-adjusted histologic remission rates of 69% to 76% across three tested doses, according to Uniquity. The differences were statistically significant, with p-values below 0.001.

Patients receiving solrikitug also experienced placebo-adjusted reductions of 8.8 to 12.6 points on the Dysphagia Symptom Questionnaire, which measures the frequency and severity of swallowing difficulties. All three doses demonstrated statistically significant improvements over placebo.

The results provide clinical support for advancing solrikitug into late-stage testing, a critical step toward potential regulatory approval.

READ:  Mineralys Drug Sustains Blood Pressure Reduction Ahead of FDA Decision

Uniquity said discussions with the U.S. Food and Drug Administration following Phase 2 indicated that a single pivotal Phase 3 trial, supported by confirmatory evidence from ALAMERE, could form the clinical basis for a planned biologics license application.

The company expects to initiate that study during the first quarter of 2027.

Solrikitug is a monoclonal antibody designed to inhibit thymic stromal lymphopoietin, or TSLP, a protein involved in inflammatory immune responses. The drug was licensed from Merck & Co. and is being developed for gastrointestinal and respiratory conditions.

In ALAMERE, patients received subcutaneous injections of 125, 250 or 500 milligrams every four weeks.

The randomized, double-blind, placebo-controlled trial evaluated changes in esophageal tissue inflammation and swallowing symptoms, along with additional measures of disease activity.

Uniquity reported improvements in endoscopic findings, histologic disease activity and the number of days patients experienced no swallowing difficulties.

The company characterized the treatment as well tolerated, with a favorable safety profile. Participants continue to be monitored through 52 weeks to evaluate the durability of treatment response and longer-term safety.

READ:  Cabaletta Reports Yearlong Responses in Autoimmune Therapy Trials

Full trial findings are expected to be presented at a future medical conference.

“We believe these data add to the growing body of evidence that TSLP plays a central role in EoE, and we look forward to beginning our pivotal Phase 3 trial in early 2027,” said Will Kane, Uniquity’s chief executive officer.

Eosinophilic esophagitis occurs when an allergic immune response causes chronic inflammation in the esophagus. Symptoms can include difficulty swallowing, food becoming lodged in the esophagus, chest pain, vomiting and abdominal discomfort.

Persistent inflammation can lead to scarring and narrowing of the esophagus, potentially worsening swallowing difficulties over time.

Uniquity cited research estimating that approximately 470,000 Americans have the condition, with prevalence increasing roughly fivefold since 2009.

Dr. Evan Dellon, a professor of medicine and director of the Center for Esophageal Diseases and Swallowing at the University of North Carolina School of Medicine, served as a primary investigator in ALAMERE.

READ:  Mineralys Drug Sustains Blood Pressure Gains Ahead of FDA Decision

“If these results are confirmed in a pivotal trial, I think solrikitug could offer substantial benefit for the treatment of EoE, while also potentially offering significant convenience through an extended dosing interval,” Dellon said.

Uniquity is evaluating whether solrikitug could eventually be administered less frequently than every four weeks, potentially differentiating the treatment from other therapies. The Phase 2 study used four-week dosing intervals.

The company is also nearing completion of separate Phase 2 studies evaluating solrikitug in asthma and chronic obstructive pulmonary disease.

Those programs could expand the drug’s potential applications beyond gastrointestinal disease.

Uniquity is additionally exploring bispecific antibodies and combination therapies that would target TSLP alongside other inflammatory pathways.

The company, backed by Blackstone Life Sciences, is pursuing those programs as part of a broader development strategy focused on immune-mediated diseases.

Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.